Rachel Haurwitz, Caribou president and CEO

Along­side tiny da­ta drop, Cari­bou plans dose es­ca­la­tion for its first off-the-shelf CAR-T tri­al

In May, Cari­bou Bio­sciences shared im­pres­sive ear­ly da­ta on its first tri­al for an off-the-shelf CAR-T ther­a­py, dis­clos­ing that four of five pa­tients suf­fer­ing from B cell non-Hodgkin’s lym­phoma had a com­plete re­sponse.

With its EHA pre­sen­ta­tion com­ing up Sat­ur­day, the Jen­nifer Doud­na-found­ed biotech has un­wrapped more da­ta on its lead can­di­date. As of May, the biotech has re­sults from one more pa­tient in its Phase I tri­al — a sixth pa­tient who had an ini­tial com­plete re­sponse, but saw their can­cer progress three months af­ter re­ceiv­ing the CAR-T in­fu­sion.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters